Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid.

By A. Parés, L. Caballería, J. Rodés. Gastroenterology, 2006

752 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2018, methodology): “(148) Biochemical response should be assessed after 1 year of treatment with UDCA using one of many published criteria shown in Table 1.(60, 77-79, 149-152) When one of these binary definitions for response to UDCA is used, up to 40% of PBC patients will have an inadequate response to treatment.”
EASL Clinical Practice Guidelines: management of cholestatic liver diseases. (2009, result): “Interestingly, a ‘‘good biochemical response” to UDCA defined as a decrease in AP >40% of pretreatment levels or normalization at one year (‘‘Barcelona criteria”) was associated with an excellent 95% transplant-free survival at 14 years of follow-up, similar to that predicted for the standardized po”
Clostridium scindens baiCD and baiH genes encode stereo-specific 7α/7β-hydroxy-3-oxo-Δ4-cholenoic acid oxidoreductases (2008, background): “UDCA is an important therapeutic agent for the treatment of cholestatic liver disease (15-18) and its administration has been suggested to prevent colon cancer (19-21).”